S25-550 Antibody-Targeted Molecular Glue Degraders for Selective Cancer Therapy Stanford researchers have developed degrader-antibody conjugates that deliver hyper-potent molecular glue degraders directly to tumor cells. Steven Corsello Nathanael Gray Md Abdullah Al Noman Tinghu Zhang
S24-180 Novel ENPP1 and ENPP3 Inhibitors for Cancer Immunotherapy Stanford researchers have developed novel ENPP1 and ENPP3 inhibitors for cancer immunotherapy. ENPP1 inhibitors have previously been reported but ENPP3 is a newly discovered target. Nathanael Gray Tinghu Zhang Md Abdullah Al Noman Alby Joseph Daniel Hugo Fernandez Fleischhauer Lingyin Li Jacqueline Carozza